Evaluation of the epidemiological and economic impact of the ADLIFE intervention on medium- to long-term in patients with advanced chronic disease

Tools

McCann, Lisa and Maguire, Roma and Morton, Alec and Koutsouradis, Konstantinos, ADLIFE Consortium (2025) Evaluation of the epidemiological and economic impact of the ADLIFE intervention on medium- to long-term in patients with advanced chronic disease. Frontiers in Public Health, 13. 1682492. ISSN 2296-2565 (https://doi.org/10.3389/fpubh.2025.1682492)

[thumbnail of Larranaga-etal-FPH-2025-Evaluation-of-the-epidemiological-and-economic-impact-of-the-ADLIFE-intervention]
Preview
 Text. Filename: Larranaga-etal-FPH-2025-Evaluation-of-the-epidemiological-and-economic-impact-of-the-ADLIFE-intervention.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

Introduction: Patients with advanced chronic disease (ACD) experience transitions in their clinical stability, leading to increased healthcare resource use and costs. EU-funded ADLIFE digital intervention aimed to ensure their quality of life through individualised care plans, clinical decision-making support, and patient empowerment. This study assessed the impact and sustainability of ADLIFE. Materials and methods: Target population included patients aged ≥55 years with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD). First, a discrete event simulation (DES) model was developed using data from Osakidetza-Basque Health Service to represent the natural history of the disease. Second, ADLIFE intervention was implemented in four pilot sites: Spain, England, Israel and Denmark. Intervention effect was quantified by comparing resource use between control and intervention groups. Finally, a budget impact analysis (BIA) was conducted by extrapolating the burden of the disease to 2030 under two scenarios: conventional and ADLIFE. Results: ADFLIFE intervention involved 370 patients (185 intervention, 185 control). Emergency visits and consultations with primary care professionals decreased significantly, while specialist consultations increased. Depending on the pilot site, projections estimated that ACD prevalence will increase by 37–50% by 2030, increasing associated costs. Under the ADLIFE scenario, the burden of the disease could be reduced by 1–2%, resulting in cumulative savings of €4–58 million. Discussion: Projections indicated a major challenge ahead due to a rise in ACD prevalence, highlighting the need for timely and effective healthcare responses. ADLIFE improved patient care and resource management, and its adoption could help reduce the disease burden and generate sustained long-term savings.

ORCID iDs

McCann, Lisa ORCID logoORCID: https://orcid.org/0000-0002-5322-5778, Maguire, Roma ORCID logoORCID: https://orcid.org/0000-0001-7935-3447, Morton, Alec ORCID logoORCID: https://orcid.org/0000-0003-3803-8517 and Koutsouradis, Konstantinos ORCID logoORCID: https://orcid.org/0000-0002-3472-0722;
CORE (COnnecting REpositories)